Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuwellis (NUWE)
NASDAQ:NUWE
Nuwellis (NUWE) Stock Price & Analysis
548 Followers
NUWE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.34 - $98.35
Previous Close$3.8
Volume61.92K
Average Volume (3M)269.69K
Market Cap
$1.96M
Enterprise Value$1.27M
Total Cash (Recent Filing)$1.40M
Total Debt (Recent Filing)$709.00K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 06, 2024EPS Estimate
-$7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-290.46
Shares Outstanding18,051,055
10 Day Avg. Volume2,424,677
30 Day Avg. Volume269,695
Standard Deviation0.34
R-Squared0.00551
Alpha-0.12
Financial Highlights & Ratios
Price to Book (P/B)4.27
Price to Sales (P/S)1.49
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.14
Enterprise Value/Gross Profit0.25
Enterprise Value/Ebitda-0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Nuwellis News
PremiumCompany Announcements
Nuwellis Achieves First QUELIMMUNE™ Sale, Cautions Investors
PremiumCompany Announcements
Nuwellis Ends Stock Sale Agreement with Ladenburg Thalmann
Bulls Say, Bears Say
Bulls Say
Product ExpansionKey highlights include expansion of its Aquadex system into additional pediatric sites, positive clinical data publications, and FDA approval of a specialty dual lumen 12cm catheter.
Revenue GrowthPediatric revenue grew 40% year-over-year, led by a 54% increase.
Sales PerformanceGrowth in consumable sales, which were up 11% year-over-year and accounted for 82% of first-quarter revenue.
Bears Say
Capital ConstraintsNear-term uncertainty regarding ongoing capital constraints is concerning.
Financial Performance1Q24 revenue slightly below estimate and a narrower GAAP loss per share.
Market ListingNUWE was notified that it did not meet the minimum closing bid requirement for continued listing on the Nasdaq exchange.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $3.34 and its highest was $98.35 in the past 12 months.
What is Nuwellis’s market cap?
Currently, no data Available
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on May 07, 2024. The company reported -$21 earnings per share for the quarter, beating the consensus estimate of -$37.1 by $16.1.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -$7.
How many shares outstanding does Nuwellis have?
Nuwellis has 515,744 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$21 in its last earnings report, beating expectations of -$37.1. Following the earnings report the stock price went up 54.181%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
---
Nuwellis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 13.3%
Last 30 Days ▼ 13.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.25%
12-Months-Change
Fundamentals
Return on Equity
-248.18%
Trailing 12-Months
Asset Growth
-63.95%
Trailing 12-Months
Company Description
Nuwellis
CHF Solutions, Inc. is a medical device company, which engages in the provision of products for the treatment of fluid overload. Its product include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
---
NUWE Earnings Call
Q1 2024
0:00 / 0:00
---
NUWE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering NUWE
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a buy rating 7 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---